This effect was paradoxical, as BRAFi is known to inhibit glycolysis in BRAF‐mutated melanomas.17, 18, 33, 34 Accordingly, our ex vivo analysis of sensitive melanoma xenografts showed significantly lower mRNA levels of GLUT1, HK2 and PDK1 in the treated group, as well as lower C‐MYC and GLUT1 protein levels. Here, SLC2A1 is linked to melanoma.